<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407287</url>
  </required_header>
  <id_info>
    <org_study_id>828397</org_study_id>
    <nct_id>NCT03407287</nct_id>
  </id_info>
  <brief_title>Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status</brief_title>
  <acronym>PIVA</acronym>
  <official_title>Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status: An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effects of fluid alternations, hemodynamic changes,
      mechanical ventilation, pharmacologic agents, positional changes, and comorbidities on the
      Peripheral Intravenous waveform Analysis (PIVA) signal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravascular volume status determination remains elusive. Standard vital sign monitoring,
      including heart rate and blood pressure, fails to detect intravascular volume depletion and
      volume overload. Likewise, invasive monitoring is fraught with risk including vascular injury
      and central line associated infections. As such, a minimally-invasive mechanism to overcome
      the barriers of standard monitoring to detect volume status derangement, would be highly
      valuable. The goal of the study is to perform a series of observational feasibility studies
      in healthy and hospitalized subjects to determine effects of fluid alternations, hemodynamic
      changes, mechanical ventilation, pharmacologic agents, positional changes, and comorbidities
      on the PIVA signal
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of PIVA score to standard hemodynamic monitors</measure>
    <time_frame>Baseline to end of monitoring (Approximately 180 minutes)</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Distributive Shock</condition>
  <condition>Hypotension and Shock</condition>
  <condition>Decompensated Congestive Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>High Risk Non-cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Systemic inflammatory response syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Distributive shock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasoactive and inotropic agents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Decompensated congestive heart failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients undergoing high risk non-cardiac surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Intravenous Analysis (PIVA)</intervention_name>
    <description>Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV</description>
    <arm_group_label>Systemic inflammatory response syndrome</arm_group_label>
    <arm_group_label>Distributive shock</arm_group_label>
    <arm_group_label>Vasoactive and inotropic agents</arm_group_label>
    <arm_group_label>Decompensated congestive heart failure</arm_group_label>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>Patients undergoing high risk non-cardiac surgery</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care invasive vascular monitoring</intervention_name>
    <description>Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.</description>
    <arm_group_label>Systemic inflammatory response syndrome</arm_group_label>
    <arm_group_label>Distributive shock</arm_group_label>
    <arm_group_label>Vasoactive and inotropic agents</arm_group_label>
    <arm_group_label>Decompensated congestive heart failure</arm_group_label>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>Patients undergoing high risk non-cardiac surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IV bolus of normal saline solution</intervention_name>
    <description>500 mL IV bolus of normal saline solution</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard noninvasive vascular monitoring</intervention_name>
    <description>Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.</description>
    <arm_group_label>Systemic inflammatory response syndrome</arm_group_label>
    <arm_group_label>Distributive shock</arm_group_label>
    <arm_group_label>Vasoactive and inotropic agents</arm_group_label>
    <arm_group_label>Decompensated congestive heart failure</arm_group_label>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>Patients undergoing high risk non-cardiac surgery</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Noninvasive vascular monitoring with Starling SV (Cheetah Medical, Inc)</intervention_name>
    <description>Noninvasive vascular monitoring with Starling SV (Cheetah Medical, Inc)</description>
    <arm_group_label>Systemic inflammatory response syndrome</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Systemic Inflammatory Response Syndrome

        Inclusion criteria:

          -  Patients in the hospital who meet 2 of the 4 SIRS criteria.

          -  Temperature &gt;38° C or less than &lt;36° C

          -  Heart rate &gt;90 beats/min

          -  Respiratory rate &gt;20 breaths/min or PaCO2 &lt;32 torr

          -  WBC &gt;12,000 cell/mm3, &lt;4,000 cells/mm3, or &gt;10% immature (band) forms

        Exclusion criteria:

          -  Ventricular assist devices, IABP, VAD, ECMO or any other mechanical cardiac support

        Distributive Shock

        Inclusion Criteria:

          -  Cardiopulmonary bypass for cardiac procedures within one hour of arriving in the ICU
             post-op.

        Exclusion Criteria:

          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and
             extracorporeal membrane oxygenation), ongoing ACLS, severe tricuspid regurgitation or
             stenosis, patient with restrictive cardiomyopathies (cardiac amyloidosis), patients
             receiving pulmonary vasodilators (nitric oxide, sodium nitroprusside, sildenafil),
             atrial fibrillation, congenital heart disease, female patients who are pregnant or
             lactating, or patients with known psychiatric or neurological disease who are unable
             to consent. Patients who do not have a functional peripheral IV as part of standard
             care.

        Vasoactive and Inotropic Agents

        Inclusion Criteria:

          -  Hospitalized patients with central venous access and pulmonary arterial catheter in
             place, requiring infusion of vasoactive and/or inotropic agents.

        Exclusion Criteria:

          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and
             extracorporeal membrane oxygenation), ongoing ACLS, severe tricuspid regurgitation or
             stenosis, patient with restrictive cardiomyopathies (cardiac amyloidosis), patients
             receiving pulmonary vasodilators (nitric oxide, sodium nitroprusside, sildenafil),
             atrial fibrillation, congenital heart disease, female patients who are pregnant or
             lactating, or patients with known psychiatric or neurological disease who are unable
             to consent. Patients who do not have a functional peripheral IV as part of standard
             care.

        Decompensated Congestive Heart Failure

        Inclusion Criteria:

          -  Patients presenting to VUMC with the diagnosis of congestive heart failure.

        Exclusion Criteria:

          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and
             extracorporeal membrane oxygenation), ongoing ACLS, severe tricuspid regurgitation or
             stenosis, patient with restrictive cardiomyopathies (cardiac amyloidosis), patients
             receiving pulmonary vasodilators (nitric oxide, sodium nitroprusside, sildenafil),
             atrial fibrillation, congenital heart disease, female patients who are pregnant or
             lactating, or patients with known psychiatric or neurological disease who are unable
             to consent. Patients who do not have a functional peripheral IV as part of standard
             care.

        Atrial Fibrillation

        Inclusion Criteria:

          -  Patients undergoing right heart catheterization in atrial fibrillation.

        Exclusion Criteria:

          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and
             extracorporeal membrane oxygenation), ongoing ACLS, severe tricuspid regurgitation or
             stenosis, patient with restrictive cardiomyopathies (cardiac amyloidosis), patients
             receiving pulmonary vasodilators (nitric oxide, sodium nitroprusside, sildenafil),
             congenital heart disease, female patients who are pregnant or lactating, or patients
             with known psychiatric or neurological disease who are unable to consent. Patients who
             do not have a functional peripheral IV as part of standard care.

        High Risk Non-cardiac Surgery

        Inclusion Criteria:

          -  Patients presenting for high-risk non-cardiac (major vascular, thoracic, or upper
             abdominal) surgery.

        Exclusion Criteria:

          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and
             extracorporeal membrane oxygenation), ongoing ACLS, severe tricuspid regurgitation or
             stenosis, patient with restrictive cardiomyopathies (cardiac amyloidosis), patients
             receiving pulmonary vasodilators (nitric oxide, sodium nitroprusside, sildenafil),
             atrial fibrillation, congenital heart disease, female patients who are pregnant or
             lactating, patients with known psychiatric or neurological disease who are unable to
             consent, or any other medical condition which, in the opinion of the investigator,
             would place the patient at undue risk from participation in the trial. Patients who do
             not have a functional peripheral IV as part of standard care.

        Healthy Volunteers

        Inclusion Criteria:

          -  Subject age &gt;21 years with ASA 1 or 2 status equivalent.

        Exclusion Criteria:

          -  Any significant comorbidities or systemic illness. Inability to locate an appropriate
             vein for cannulation by visual inspection; inability to obtain IV catheter within 3
             attempts; Subject refusal at any time. Systolic blood pressure &gt;160mmHg or &lt;90 mmHg;
             Diastolic blood pressure &gt;100mmHg or &lt;30mmHg; pulse rate &gt;110 or &lt;30 beats per minute;
             respiratory rate&gt;30 or &lt;5 breaths per minute. Patients on medications for
             hypertension, diabetes, or any vasoactive medication (phenylephrine/Sudafed/Afrin
             nasal spray within 48 hours of study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly L. Kohorst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly L. Kohorst, MD</last_name>
    <phone>615-322-4056</phone>
    <email>kelly.kohorst@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gail Mayo, RN</last_name>
    <phone>615-936-1705</phone>
    <email>gail.mayo@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly L. Kohorst, MD</last_name>
      <phone>615-322-4056</phone>
      <email>kelly.kohorst@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gail Mayo, RN</last_name>
      <phone>615-936-1705</phone>
      <email>gail.mayo@vanderbilt.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Kelly Kohorst</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

